At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 146 enrolled
Drug / intervention
Vatiquinone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Parallel-Arm, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Friedreich Ataxia (MOVE-FA)
In Brief
A Phase 3 clinical trial evaluating Vatiquinone and Placebo for Friedreich Ataxia. Completed, enrolled 146 participants across 14 sites in 9 countries.
Detailed Summary
The primary objective of the study is to evaluate the efficacy (using the modified Friedreich Ataxia Rating Scale \[mFARS\]) and safety of vatiquinone in participants with Friedreich ataxia (FA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFriedreich Ataxia
CountriesAustralia, Brazil, Canada, France, Germany, Italy, New Zealand, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartDec 2020
Primary CompletionApr 2023
Study CompletionOct 2023
TodayJul 2026
First PostedOct 6, 2020
Enrollment StartDec 17, 2020
Primary CompletionApr 4, 2023
Study CompletionOct 2, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.7 years ago
Interventions
Vatiquinonedrug
Vatiquinone will be administered per dose and schedule specified in the arm.
Placebodrug
Placebo will be administered per schedule specified in the arm.